<DOC>
	<DOCNO>NCT01133002</DOCNO>
	<brief_summary>Primary Objective : - To obtain prospective , clinical practice-based data symptomatic VTE manage low molecular weight heparin ( LMWH ) enoxaparin Canadian outpatient setting . Secondary Objective : - To describe demographic clinical characteristic patient symptomatic VTE include characteristic VTE , VTE risk factor bleed risk factor . - To assess frequency patient characteristic would necessitate adjustment dose duration enoxaparin therapy , e.g . high BMI , impair creatinine clearance , advanced age , cancer-associated VTE . - To assess degree adherence clinical practice Consensus Guidelines ( ACCP/American College chest Physician 2008 ) management acute VTE , vi vi : - Appropriate dose enoxaparin - Recommended duration initial LMWH therapy - Adequate overlap LMWH vitamin K antagonist ( VKA ) - Recommended duration longterm VKA - Frequency use LMWH monotherapy treat cancer-related VTE - To access safety outcome ( include bleed recurrent VTE ) - To describe utilization resource due bleed recurrent VTE treatment period .</brief_summary>
	<brief_title>Canadian Outpatient VTE Management Registry</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Objectively confirm VTE Initiation enoxaparin treatment within Day 010 diagnosis VTE : Outpatients treat enoxaparin + VKA combination permit receive initial treatment enoxaparin maximum 48 hour 2 treatment dos precede entry study Outpatients enoxaparin monotherapy permit receive 10 day treatment enoxaparin precede entry study . Exclusion criterion : Medical psychiatric disorder associate altered cognition mentation precludes understand informed consent process . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>